Delapril is an ACE inhibitor used as an antihypertensive drug in some European and Asian countries but not in America. It is taken orally, available in 15 mg and 30 mg tablets. Chemically delapril is administered as a prodrug that is rapidly metabolized to the pharmacologically active diacid metabolite delaprilat which inhibits angiotensin converting enzyme and reduces angiotensin II formation and aldosterone release. The molecule is formulated for oral absorption with hepatic first pass conversion to the active metabolite; pharmacodynamic effects reduce systemic vascular resistance and can improve cardiac preload and afterload in susceptible patients. Standard product information notes contraindications common to ACE inhibitors including pregnancy and a history of angioedema, and dosing is individualized by clinical response, renal function and concomitant therapies. Quality control and labeling reflect typical excipient content, tablet hardness and dissolution criteria consistent with regulatory standards applied in the markets where it is approved.
Parent: Delapril
Typical related substances observed during synthesis, manufacturing and stability include the active metabolite delaprilat, monoester and diacid hydrolysis products, oxidative and N-oxide variants, and trace synthetic byproducts and residual solvents stemming from starting materials and reagents; these are monitored by validated chromatographic methods such as HPLC with UV detection and by LC-MS for structural confirmation. As a practical quality control approach manufacturers commonly set acceptance criteria consistent with ICH Q3A and Q3B principles, for example individual specified related compounds frequently limited to 0.1 to 0.5 percent by area and total impurities limited to about 1.0 percent, with higher thresholds requiring qualification and toxicological justification; genotoxic or class 1 impurities are controlled to significantly lower limits and residual solvents are controlled to pharmacopeial limits. Batch release and stability specifications therefore combine identification, reporting and acceptance thresholds together with forced-degradation profiling to ensure impurity profiles remain within qualified limits throughout shelf life.
Delapril is used to lower blood pressure by inhibiting the angiotensin converting enzyme; it is prescribed for hypertension and may be used in clinical situations where an ACE inhibitor is indicated, with dosing and monitoring adjusted for renal function and concomitant medications.
Trandolapril is an ACE inhibitor with a safety profile similar to other drugs in the class; it can be effective and well tolerated for many patients but carries class risks including cough, hyperkalemia, renal function changes and rare angioedema, and it is contraindicated in pregnancy and in patients with a prior history of ACE inhibitor related angioedema.
Ramipril is an ACE inhibitor indicated for treatment of hypertension, for reducing cardiovascular morbidity and mortality in patients at risk, and for certain patients with heart failure or after myocardial infarction; it is also used to delay progression of diabetic nephropathy in appropriate patients.
Yes, trandolapril remains available in many countries under various brand names and as generic products, but availability and marketed formulations vary by country and regulatory approval status so local formularies and product monographs should be consulted.
